Meroxest improves the prognosis of immunocompetent C57BL/6 mice with allografts of E0771 mouse breast tumor cells.
BACKGROUND
Recently, we have reported the antitumor properties of a new family of synthetic merosesquiterpenes, among which meroxest is highlighted, since it has high activity and specificity for ER+breast cancer cells. In this paper, we characterize allografts of ER+E0771 mouse breast tumor cells in immunocompetent C57BL/6 mice, and also analyze the effect of meroxest on the prognosis of the disease.


METHODS
Twenty female C57BL/6 mice were injected with 106E0771 cells. Once the tumors reached the appropriate size, the mice were divided into two groups, one control and another treated orally with 15 mg/kg of meroxest. After 20 days, tumor samples were taken for histopathological study and for determination of the expression of the prognostic markers Ki67 and vascular endothelial growth factor (VEGF) by immunofluorescence.


RESULTS
In sections stained with hematoxylin-eosin, we observed that tumors have a well-defined capsule enclosing E0771 tumor cells. The central area of tumors contains necrotic regions with leukocyte infiltration. Meroxest treatment significantly reduces tumor size (68%,p< 0.05), induces changes in its structure, decreases the degree of leukocyte infiltration, and significantly reduces the expression of Ki67 (33%,p< 0.05) and VEGF (82%,p< 0.05).


CONCLUSIONS
Meroxest improves the prognosis of mice since it reduces leukocyte infiltration, and decreases the expression of Ki67 and VEGF markers. Consequently, the merosesquiterpene could become a useful antiangiogenic drug in the treatment of breast cancer. These results encourage us to deepen the study of meroxest, in order to find more evidence that supports the convenience of its evaluation in a clinical study or trial.
Institute of Biopathology and Regenerative Medicine (IBIMER), University of Granada, Granada, Spain; PhD Program in Biomedicine, University of Granada, Granada, Spain.
Esther
E
Carrasco
Department of Cardiovascular Surgery, Virgen de las Nieves Hospital, Granada, Spain.
Jose Manuel
JM
Garrido
Institute of Biopathology and Regenerative Medicine (IBIMER), University of Granada, Granada, Spain.
Pablo Juan
PJ
Álvarez
Department of Organic Chemistry, Institute of Biotechnology, University of Granada, Granada, Spain.
Enrique
E
Álvarez-Manzaneda
Department of Organic Chemistry, Institute of Biotechnology, University of Granada, Granada, Spain.
Rachid
R
Chahboun
Department of Organic Chemistry, Institute of Biotechnology, University of Granada, Granada, Spain.
Ibtissam
I
Messouri
Institute of Biopathology and Regenerative Medicine (IBIMER), University of Granada, Granada, Spain.
Consolación
C
Melguizo
Institute of Biopathology and Regenerative Medicine (IBIMER), University of Granada, Granada, Spain.
Antonia
A
Aránega
Institute of Biopathology and Regenerative Medicine (IBIMER), University of Granada, Granada, Spain.
Fernando
F
Rodríguez-Serrano
Ki67; breast cancer; in vivo; merosesquiterpene; vascular endothelial growth factor
Breast. 2011 Oct;20 Suppl 3:S82-6
22015299
Expert Rev Anticancer Ther. 2014 Feb;14(2):163-72
24308686
Org Lett. 2005 Apr 14;7(8):1477-80
15816731
Vasc Cell. 2013 May 02;5(1):9
23638734
Eur J Clin Invest. 2014 Jul;44(7):678-87
24766664
Exp Ther Med. 2011 Sep;2(5):821-826
22977582
Arch Med Sci. 2013 Jun 20;9(3):466-71
23847668
Cancer Biol Ther. 2011 May 15;11(10):910-7
21451264
Eur J Med Chem. 2014 May 22;79:1-12
24704691
Int J Nanomedicine. 2014 Mar 11;9:1339-46
24648732
Anticancer Res. 2014 Mar;34(3):1071-7
24596345
Arch Med Sci. 2012 May 9;8(2):303-9
22662004
Biomed Res Int. 2014;2014:628217
24783217
N Engl J Med. 1971 Nov 18;285(21):1182-6
4938153
EMBO J. 2013 Mar 6;32(5):617-28
23395906
Br J Cancer. 2012 Aug 21;107(5):864-73
22878371
Ann Oncol. 2012 Dec;23(12):2997-3006
23166150
Mol Oncol. 2012 Aug;6(4):418-27
22521242
Clin Med Insights Oncol. 2010 Apr 20;4:15-34
20567632
Cell. 2011 Mar 4;144(5):646-74
21376230
J Mammary Gland Biol Neoplasia. 2012 Dec;17(3-4):229-39
23011602
Histopathology. 2013 May;62(6):963-5
23551496
Int J Oncol. 2014 Jul;45(1):209-18
24789042
Anticancer Res. 2005 Nov-Dec;25(6B):3905-15
16312045
J Breast Cancer. 2014 Mar;17(1):40-6
24744796
Nat Med. 2003 Jun;9(6):669-76
12778165
Mol Carcinog. 2010 May;49(5):500-7
20422714
Arch Med Sci. 2015 Mar 16;11(1):220-9
25861310
Beijing Da Xue Xue Bao. 2012 Oct 18;44(5):708-14
23073579
Breast Cancer Res Treat. 2014 Jan;143(1):1-9
24272079
Leukemia. 2008 May;22(5):971-9
18401414
Q J Nucl Med Mol Imaging. 2013 Dec;57(4):312-21
24322788
Arch Med Sci. 2013 Jun 20;9(3):472-8
23847669
Carcinogenesis. 2009 Jul;30(7):1073-81
19468060
Jpn J Clin Oncol. 2014 Mar;44(3):197-207
24474817
J Clin Pathol. 2013 Jun;66(6):512-6
23436927
Arch Med Sci. 2012 Sep 8;8(4):655-8
23056077
Recent Pat Anticancer Drug Discov. 2013 Sep;8(3):203-15
23157341
Chem Pharm Bull (Tokyo). 2009 Oct;57(10):1103-6
19801866
Mini Rev Med Chem. 2013 Apr;13(4):530-40
23317499
Nat Rev Cancer. 2012 Mar 15;12 (4):298-306
22419253
Arch Med Sci. 2013 Feb 21;9(1):79-85
23515230
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
21296855
J Clin Oncol. 2005 Oct 1;23(28):7212-20
16192605
Cell. 2011 Sep 16;146(6):873-87
21925313
Blood. 2006 Dec 1;108(12 ):3906-12
16912222
Clin Oncol (R Coll Radiol). 2013 Feb;25(2):117-26
23219233
Arch Med Sci. 2012 May 9;8(2):227-35
22661994
J Nucl Med. 2010 Apr;51(4):501-4
20237033